OGEN vs. PRPH, NERV, SPRB, CING, NRSN, BGXX, HCWB, IMNN, AIM, and CRVO
Should you be buying Oragenics stock or one of its competitors? The main competitors of Oragenics include ProPhase Labs (PRPH), Minerva Neurosciences (NERV), Spruce Biosciences (SPRB), Cingulate (CING), NeuroSense Therapeutics (NRSN), Bright Green (BGXX), HCW Biologics (HCWB), Imunon (IMNN), AIM ImmunoTech (AIM), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry.
Oragenics vs.
Oragenics (NYSE:OGEN) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, community ranking, institutional ownership, valuation, analyst recommendations, risk and media sentiment.
ProPhase Labs received 114 more outperform votes than Oragenics when rated by MarketBeat users. Likewise, 50.00% of users gave ProPhase Labs an outperform vote while only 0.00% of users gave Oragenics an outperform vote.
ProPhase Labs has higher revenue and earnings than Oragenics. ProPhase Labs is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks.
Oragenics has a net margin of 0.00% compared to ProPhase Labs' net margin of -217.64%. ProPhase Labs' return on equity of -62.92% beat Oragenics' return on equity.
In the previous week, Oragenics had 3 more articles in the media than ProPhase Labs. MarketBeat recorded 3 mentions for Oragenics and 0 mentions for ProPhase Labs. Oragenics' average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.
18.7% of Oragenics shares are owned by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are owned by institutional investors. 10.1% of Oragenics shares are owned by company insiders. Comparatively, 20.7% of ProPhase Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Oragenics has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.3, suggesting that its share price is 130% less volatile than the S&P 500.
ProPhase Labs has a consensus target price of $11.00, indicating a potential upside of 1,712.19%. Given ProPhase Labs' stronger consensus rating and higher probable upside, analysts clearly believe ProPhase Labs is more favorable than Oragenics.
Summary
ProPhase Labs beats Oragenics on 11 of the 17 factors compared between the two stocks.
Get Oragenics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oragenics Competitors List
Related Companies and Tools
This page (NYSE:OGEN) was last updated on 1/21/2025 by MarketBeat.com Staff
Free OGEN Stock Alerts